AEON Biopharma (AEON) vs Dare Bioscience (DARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dare Bioscience (DARE) has outperformed AEON Biopharma (AEON) over the past year, losing 66.3% versus a loss of 66.7%. AEON Biopharma is the larger company by market cap ($15.5 million vs $15.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | DARE |
|---|---|---|
| Share price | $0.31 | $0.7722 |
| Market cap | $15.46M | $15.19M |
| 1-day change | -0.40% | -2.25% |
| YTD return | -71.70% | -59.99% |
| 1-year return | -66.71% | -66.28% |
| 5-year return | — | -95.90% |
| EPS (TTM) | $-4.39 | $-0.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $3.78 |
| 52-week low | $0.177 | $0.69 |
| Distance from 52-week high | -78.62% | -79.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +487.10% | +978.74% |
| Average volume | 8.59M | 524.37K |
| Shares outstanding | 49.88M | 19.67M |
| Employees | 8 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Healthcare · Biotechnology · 8 employees
About Dare Bioscience
DARE stock →Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Healthcare · Biotechnology · 21 employees
AEON vs DARE FAQ
Which is bigger, AEON Biopharma or Dare Bioscience?
AEON Biopharma (AEON) is larger, with a market capitalization of $15.46M compared with $15.19M for Dare Bioscience (DARE).
Which stock has performed better over the past year, AEON or DARE?
DARE returned -66.28% over the past 12 months, compared with -66.71% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Dare Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.